Welcome to our dedicated page for Novanta news (Ticker: NOVT), a resource for investors and traders seeking the latest updates and insights on Novanta stock.
Novanta Inc. reports developments as a Nasdaq-listed supplier of core technology solutions for medical, life science and advanced industrial original equipment manufacturers. Its updates center on precision medicine, precision manufacturing, robotics and automation, and advanced surgery, including laser beam steering and scanning, laser sources, robotic and precision motion technologies, medical insufflators, endoscopic pumps and integrated operating room technologies.
Company news commonly covers quarterly earnings releases, conference calls, investor presentations, OEM design wins, product and technology collaborations, and capital actions tied to balance-sheet and securities structure. Recent themes include motion control and sensing technologies for robotics certification environments and tangible equity unit financing.
Novanta (Nasdaq:NOVT) announced that Chief Financial Officer Robert Buckley and Chief Operating Officer Chuck Ravetto will present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026, in White Plains, New York.
Novanta (NASDAQ:NOVT) entered a securities purchase agreement for a $300 million private placement of common shares to institutional and other accredited investors. Investors will buy 2,142,857 shares at $140.00 per share. Closing is expected on or about June 11, 2026, subject to customary conditions.
The shares are unregistered under the Securities Act and may only be resold under an effective registration statement or exemption. A registration rights agreement requires Novanta to register the resale of these shares.
Novanta (NASDAQ:NOVT) agreed to acquire Riverpoint Medical, a minimally invasive surgical consumables leader, for $1.2 billion upfront plus a $250 million milestone in Q1 2027. Closing is expected in Q3 2026.
The deal is projected to double recurring medical consumables revenue to about $300 million, deepen medical revenue mix to 60%, add a $2 billion addressable market, and be accretive to adjusted EPS and margins while keeping net leverage near 2.7x.
Novanta (Nasdaq:NOVT) announced that Chief Financial Officer Robert Buckley will present at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, in New York, NY.
The appearance highlights Novanta’s participation in a major healthcare investor conference.
Novanta (Nasdaq:NOVT)/b) announced that Chief Financial Officer is scheduled to present at the Baird 2026 Global Consumer, Technology & Services Conference on Wednesday, June 3, 2026, in New York, NY.
The event offers investors an opportunity to hear from Novanta's leadership.
Novanta (Nasdaq:NOVT) reported first quarter 2026 GAAP revenue of $257.7 million, up 10.4% year-over-year. GAAP net income was $21.1 million with diluted EPS of $0.51. Adjusted EBITDA rose 14.2% to $57.1 million and Adjusted diluted EPS increased 9.5% to $0.81.
Bookings grew 37% year-over-year with a 1.10 book-to-bill ratio. Operating cash flow was $51.6 million, up from $31.7 million. For full year 2026, Novanta expects GAAP revenue of $1.04–$1.055 billion, Adjusted EBITDA of $245–$250 million, and Adjusted diluted EPS of $3.50–$3.65.
Novanta (Nasdaq: NOVT) will release its first quarter 2026 results after U.S. market close on Monday, May 11, 2026 and host a conference call on Tuesday, May 12, 2026 at 8:00 a.m. ET.
Investors can join by phone at (888) 346-3959 or via a live webcast on the company’s Investors Events & Presentations page. A replay will be available about three hours after the call through Monday, July 6, 2026.
Novanta (NASDAQ: NOVT) joined the NVIDIA Halos AI Systems Inspection Lab, the first ANAB‑accredited inspection lab for AI-driven physical systems. Novanta will work with NVIDIA to validate interoperability of its motion control and sensing technologies with NVIDIA platforms, including NVIDIA IGX Thor.
This collaboration aims to streamline OEM integration, accelerate time‑to‑market for robotics, support system‑level certification, and align Novanta hardware and subsystems with NVIDIA software for warehouse automation, industrial robotics, and humanoid platforms.
Novanta (Nasdaq: NOVT) reported Q4 2025 GAAP revenue of $258.3M (+8.5% YoY) and GAAP diluted EPS of $0.45. Q4 Adjusted Diluted EPS rose 20% to $0.91 and Adjusted EBITDA rose 17% to $60.7M. Full‑year 2025 GAAP revenue was $980.6M; Adjusted Diluted EPS was $3.29.
The company ended 2025 with $381M cash, $251M debt (Net Debt: ($121M)), a 25% increase in customer bookings and a book‑to‑bill of 1.11x. 2026 guidance: revenue $1.03–1.05B, Adjusted EBITDA $245–250M.
Novanta (Nasdaq: NOVT) will release its fourth quarter 2025 results on Tuesday, February 24, 2026. The company will hold a conference call the same day at 8:00 a.m. ET to discuss results.
Investors can join by dialing (888) 346-3959 before the call or via a live webcast on the company’s Investors > Events & Presentations page at www.novanta.com. An audio replay will be posted about three hours after the call and will remain available through Monday, April 27, 2026.